NEW YORK (GenomeWeb News) — The National Cancer Institute will dole out $1.4 million in 2007 and 2008 to between five and 10 grants to small businesses studying low-abundance small molecules in cancer, the National Institutes of Health sated in an FOA released March 6,
NCI’s goal for the research, which should focus on brain, lung, and breast cancers, is to develop “new tools and methodologies for the detection, isolation and characterization of proteins, peptides, or micro RNAs” that generally occur at concentration levels too low for current technologies to handle.
NIH said these low abundance components could be used to indicate the “onset, stage and response to therapy of cancer,” if technologies were developed to find, identify and handle them.
To develop these technologies, NIH said, more detailed knowledge of the modification patterns of these low abundance biomolecules in normal and abnormal cells is needed.
NIH said the research will include “novel adaptations or combinations of existing technologies” such as, arrays, chromatography, mass spectrometry, cell sorting and enrichment techniques, chemical modifications, and nuclear magnetic resonance.
The NCI said it will offer Phase I funding up to $300,000 over two years, with no more than $200,000 to be granted in any single year. Phase II funding will be capped at $750,000 for two years.
Eligible for-profit entities for the Small Business Innovation Research funding must be independently owned and operated, at least 51-percent US owned, with less than 500 employees.
The closing date for applications is Jan. 8, 2008.
Additional information can be found here.